PLEASANTON, Calif., Jan. 10, 2017 -- Title21 Health Solutions (www.Title21Health.com), a provider of easy-to-use and integrated software solutions to support health science organizations to improve efficiencies, compliance and patient safety is pleased to announce its selection as the enterprise quality management solution (EQMS) for Versiti. Versiti, whose affiliates include BloodCenter of Wisconsin™, Heartland Blood Centers™, Indiana Blood Center™, and Michigan Blood™, offers a comprehensive range of blood related services to help healthcare systems deliver high quality patient care.
“Versiti selected Title21 Health Solutions’ EQMS due to its robust, yet easy-to-use solutions with a very attractive ROI in the industry. It is critical that Versiti utilize an enterprise solution that supports our integration while delivering the highest efficiency and quality to maintain our competitive edge, and help us provide the highest value to our customers,” stated Meg McElligott, SBB (ASCP), chief quality officer of Versiti. “Title21 came highly recommended by two of our affiliates, Indiana Blood Center and Michigan Blood, who currently utilize Title21 and have experienced process improvements for document control and training, change management, error management, CAPA, equipment QC tracking and incident reporting.”
Title21’s EQMS is designed to facilitate quality across the enterprise while maintaining flexibility for each location’s site-specific processes. This enables multiple sites to operate on a common platform, while maintaining workflows and processes specific to their location. Permission controls ensure that each site has access to what they need while providing centralized data management, reporting and oversight at the enterprise-level. Data is highly accessible via iPads® and other tablets with robust security and 21 CFR Part 11 compliance.
“Versiti’s selection of Title21 is a testament to our ability to deliver high value and powerful functionality in today’s cost sensitive market. The scalability and breadth of our technology can support the long-term data management needs of Versiti’s service areas including transfusion medicine, transplantation, cellular therapies, hematology and oncology and genomics,” remarked Lynn Fischer, chief executive officer of Title21 Health Solutions. “We are aligned with Versiti’s mission to increase healthcare quality, improve patient outcomes and reduce costs.”
About Title21 Health Solutions
Title21 Health Solutions delivers easy-to-use, flexible and integrated technology to support health sciences organizations to gain efficiencies, improve compliance and heighten quality. Title21’s product line includes web-based quality management solutions and the most comprehensive cellular therapy software available on the market. Learn more about Title21 Health Solutions at www.Title21Health.com.
About Versiti
Versiti was formed with the mission to improve the health of patients and enable the success of our healthcare partners nationally. We provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts of Versiti affiliates result in improved patient outcomes, expanded access to care and cost efficiencies for healthcare systems nationwide. For more information, visit www.versiti.org.
Contact: Haley Roebuck [email protected]


Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Bank of America's $72.5M Epstein Settlement: What You Need to Know
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 



